Humedics GmbH, a Berlin, Germany-based specialist for mobile measurement of liver function, has closed its first venture financing round.
The company intends to use the funds, whose amount remained undisclosed, to complete the final development and early commercialization of its proprietary and CE-marked diagnostic system to determine the liver function of a patient in real time.
Led by Dr. Klaus Stöckemann, Chairman of Humedics’ board and Managing Director at Peppermint VenturePartners (the manager of the Charité Biomedical Fund), and Managing Director Wilfried Heyne, Humedics has developed a breath test (LiMAx™ test) based diagnostic system composed of the medical device FLIP™ and a new intravenous diagnostic drug preparation (13C-Methacetin). The LiMAx™ test enables the clinician to quantitatively determine the individual liver function capacity within minutes. Current applications include diagnosis of the liver function before and after liver transplantation as well as planning of liver surgeries and different diseases of the liver such as liver cirrhosis.